Placeholder

From Scorpion to Cancer

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1313. Categories: , .

Product Description

Patients diagnosed with glioma, especially primary high-grade forms of the disease, often die not long after diagnosis. And the quality of life after diagnosis is quite poor. Standard treatment, surgery followed by radiation, is not effective and, in most cases, the cancer will recur.
Now, a poisonous venom from a scorpion holds hope as an effective treatment for this deadly form of brain cancer. TransMolecular Inc., a neuroscience biotechnology company, is developing a synthetic version of chlorotoxin, a component of venom obtained from the giant yellow Israeli scorpion, Leiurus quinquestriatus, called TM-601. TM-601 is being used as a drug-delivery vehicle that binds specifically to a receptor found on primary brain tumors, or gliomas, but not normal tissues. TM-601 is a very small, stable, and versatile peptide that can cross the blood brain…

Sidebars:
131I-TM-601 Timeline
Brain Cancer Facts

Experts on this Topic
Vernon Alvarez, Ph.D. VP, Research and Development, TransMolecular Inc., Birmingham, Ala.; TransMolecular, founded in 1996, is a privately held and venture-capital backed biotechnology company that is developing products to diagnose and treat diseases of the central nervous system. For more information, visit transmolecular.com.
Matthew A. Gonda, Ph.D. President, CEO, and director, TransMolecular Inc., Birmingham, Ala.; TransMolecular, founded in 1996, is a privately held and venture-capital backed biotechnology company that is developing products to diagnose and treat diseases of the central nervous system. For more information, visit transmolecular.com.
Lyle Hohnke, Ph.D. General Partner,  Tullis-Dickerson & Co. Inc., Greenwich, Conn.; Tullis-Dickerson is a private equity group providing capital to small and midsize healthcare companies. For more information, visit tullisdickerson.com.

FEEDBACK